StockNews.AI
LLY
StockNews.AI
112 days

Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration

1. Creyon Bio collaborates with Lilly on RNA-targeted therapies using AI technology. 2. The partnership aims to streamline drug development for various diseases.

2m saved
Insight
Article

FAQ

Why Bullish?

The partnership indicates strong innovation potential for LLY, aligning with market trends favoring biotech advances. Historically, similar collaborations have led to substantial stock price increases.

How important is it?

The collaboration enhances LLY's competitive position in biotech, indicating forward momentum in innovative therapies.

Why Long Term?

Success in RNA-targeted therapies could yield significant future revenue streams based on ongoing trends in personalized medicine and biopharma.

Related Companies

MRNAPFEABBV
SAN DIEGO--(BUSINESS WIRE)-- #AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases. As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly's named targets on time.

Related News